Introduction
Osteosarcoma is one of the most common malignant tumors in young children (1, 2) . Current treatment strategies, which consist of multi-agent chemotherapy and aggressive surgery, have significantly improved the cure rate and prognosis of patients with osteosarcoma. In fact, over the past 30 years, the 5-year survival rate has increased from 10% to 70% (3) (4) (5) . Even in osteosarcoma patients with metastases at diagnosis, the 5-year survival rate has reached 20% to 30% in response to chemotherapy and surgical removal of primary and metastatic tumors (6) . However, treatment outcomes for patients with osteosarcomas have further improved over the last few years. Therefore, the development of novel therapeutic strategies is required to improve the clinical outcomes in patients with osteosarcomas.
Tumor-specific replication-competent oncolytic viruses are being developed as novel anticancer therapy, in which the promoters of cancer-related genes are used to regulate virus replication in a tumor-dependent manner. More than 85% of all human cancers express high telomerase activity to maintain the length of the telomeres during cell division, while normal somatic cells seldom show this enhance telomerase activity (7, 8) . Telomerase activity has also been detected in 44% to 81% of bone and soft tissue sarcomas (9, 10) . Telomerase activation is closely correlated with the expression of the human telomerase reverse transcriptase (hTERT) gene (11) . Based on these data, we previously developed a telomerase-specific replication-competent oncolytic adenovirus OBP-301 (Telomelysin), in which the hTERT gene promoter drives the expression of the E1A and E1B genes (12) . A phase I clinical trial of OBP-301, which was conducted in the United States on patients with advanced solid tumors, indicated that OBP-301 was well tolerated by patients (13) . Recently, we reported that OBP-301 efficiently killed human bone and soft tissue sarcoma cells (14, 15) . However, some osteosarcoma cell lines were not sensitive to the antitumor effect of OBP-301. Therefore, to efficiently eliminate tumor cells with OBP-301, its antitumor effects need to be enhanced.
Cancer gene therapy is defined as the treatment of malignant tumors via the introduction of a therapeutic tumor suppressor gene or the abrogation of an oncogene.
The tumor-suppressor p53 gene has an attractive tumor suppressor profile as a potent therapeutic transgene for induction of cell cycle arrest, senescence, apoptosis and autophagy (16) . Dual cell death pathways, such as apoptosis and autophagy, induced by p53 transactivation are mainly involved in the suppression of tumor initiation and progression. However, among the p53-downstream target genes, p21, which is most rapidly and strongly induced during the DNA damage response, mainly induces cell cycle arrest through suppression of apoptotic and autophagic cell death pathways (17, 18) . Thus, p21 suppression may be a more effective strategy for the induction of apoptotic and autophagic cell death pathways in tumor cells, particularly when the tumor-suppressor p53 gene is overexpressed in tumor cells in response to cancer gene therapy.
A p53-expressing replication-deficient adenovirus (Ad-p53, Advexin) has previously been reported to induce an antitumor effect in the in vitro and in vivo settings (19, 20) as well as in some clinical studies (21) (22) (23) (24) . We recently reported that combination therapy with OBP-301 and Ad-p53 resulted in a more profound antitumor effect when compared to monotherapy with either OBP-301 or Ad-p53 (25) . Moreover, we generated armed OBP-301 expressing the wild-type p53 tumor suppressor gene (OBP-702) and showed that OBP-702 suppressed the viability of various types of epithelial malignant cells more efficiently than did OBP-301 (26) . OBP-702 induced a more profound apoptotic cell death effect when compared to Ad-p53, likely via adenoviral E1A-mediated suppression of anti-apoptotic p21 in human epithelial malignant cells. However, it remained unclear whether OBP-702 efficiently induces an antitumor effect in human non-epithelial malignant cells, including osteosarcomas.
In the present study, we investigated the in vitro cytopathic efficacy of the p53-expressing telomerase-specific replication-competent oncolytic adenovirus, OBP-702, in human osteosarcoma cells, and we compared the induction level of apoptotic and autophagic cell deaths in OBP-301-resistant human osteosarcoma cells infected with OBP-301, OBP-702 and Ad-p53. The molecular mechanism by which OBP-702 mediates induction of apoptosis and autophagy was also investigated. Finally, the in vivo antitumor effect of OBP-702 was evaluated using an orthotopic OBP-301-resistant human osteosarcoma xenograft tumor model.
Materials and Methods

Cell lines
The human osteosarcoma cell lines, HOS and SaOS-2, were kindly provided by Dr. Satoru Kyo (Kanazawa University, Ishikawa, Japan). These cells were propagated as monolayer cultures in Dulbecco's modified Eagle's medium. The human osteosarcoma cell line, U2OS, was obtained from the American Type Culture Collection (Manassas, VA, USA) and was grown in McCoy's 5a medium. The human osteosarcoma cell line, MNNG/HOS, was purchased from DS Pharma Biomedical (Osaka, Japan) and was maintained in Eagle's minimum essential medium containing serum, 100 U/ml penicillin and 100 mg/ml streptomycin. The normal human lung fibroblast cell line, NHLF, was obtained from TaKaRa Biomedicals (Kyoto, Japan).
NHLF cells were propagated as monolayer culture in the medium recommended by the manufacturer. Although cell lines were not authenticated by the authors, cells were immediately expanded after receipt and stored in liquid N 2 . Cells were not cultured for more than 5 months following resuscitation. The cells were maintained at 37C in a humidified atmosphere with 5% CO 2 .
Recombinant adenoviruses
The recombinant telomerase-specific replication-competent adenovirus OBP-301 (Telomelysin), in which the promoter element of the hTERT gene drives the expression of E1A and E1B genes, was previously constructed and characterized (12, 27) . For OBP-301-mediated induction of exogenous p53 gene expression, we recently generated OBP-702, in which a human wild-type p53 gene expression cassette was inserted into the E3 region ( Supplementary Fig. S1 ) (26) . Ad-p53 is a replication-defective adenovirus serotype 5 vector with a p53 gene expression cassette at the E1 region (19, 20) . Recombinant viruses were purified by ultracentrifugation using cesium chloride step gradients, their titers were determined by a plaque-forming assay using 293 cells, and they were stored at -80C.
Cell viability assay
Cells were seeded on 96-well plates at a density of 1 × 
Western blot analysis
SaOS-2 and MNNG/HOS cells, seeded in a 100-mm dish at a density of 1 × 
Flow cytometric analysis
To analyze the active caspase-3 expression, cells were incubated for 20 min on ice in Cytofix/Cytoperm solution (BD Biosciences, Franklin Lakes, NJ, USA), were labeled with phycoerythrin-conjugated rabbit anti-active caspase-3 mAb (BD Biosciences) for 30 min, and were then analyzed using FACS array (BD Biosciences).
To evaluate the sub-G1 population, which is a apoptosis indicator, in SaOS-2 cells after virus infection, SaOS-2 cells were seeded in a 100-mm dish at a density of 1 The concentration and quality of RNA were assessed using a Nanodrop spectrophotometer. cDNA was synthesized from 10 ng of total RNA using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems), and quantitative real-time RT-PCR was performed using the Applied Biosystems StepOnePlus TM real-time PCR System. The expressions of miR-93 and miR-106b were defined from the threshold cycle (Ct), and relative expression levels were calculated using the 2 -Ct method after normalization with reference to the expression of U6 snRNA. 
In vivo orthotopic MNNG/HOS xenograft tumor model
Three-dimensional computed tomography imaging
The tumor volume and formation of osteolytic lesions were evaluated using three-dimensional computed tomography (3D-CT) imaging (ALOKA Latheta LCT-200;
Hitachi Aloka Medical, Tokyo, Japan). The tumor volume was calculated by INTAGE Realia ® software (Cybernet Systems, Tokyo, Japan).
Histopathologic analysis
Tumors were fixed in 10% neutralized formalin and embedded in paraffin blocks. Sections were stained with hematoxylin/eosin (H&E) and analyzed by light microscopy.
Statistical analysis
Data are expressed as means ± SD. Student's t test was used to compare differences between groups. Statistical significance was defined as a P value less than 0.05.
Results
In vitro cytopathic efficacy of OBP-702 against human osteosarcoma cell lines
To evaluate the in vitro cytopathic activity of OBP-702, we used the two OBP-301-sensitive human osteosarcoma cells (HOS and U2OS) and the two OBP-301-resistant human osteosarcoma cells (SaOS-2 and MNNG/HOS) that were recently described (14) . The cell viability of each cell was assessed over 5 days after infection using the XTT assay. OBP-702 infection suppressed the viability of OBP-301-sensitive and OBP-301-resistant cells in dose-and time-dependent manners ( Fig. 1A and 1B) . When the ID 50 values of OBP-702 in all four human osteosarcoma cells were compared with those of OBP-301 calculated in a previous report (14) , all cell lines were more sensitive to OBP-702 than to OBP-301 (Table 1 ). The ID 50 values of OBP-702 were also lower than those of Ad-p53 ( Supplementary Fig. S2 ). However, OBP-702 did not exhibit any cytopathic effect in NHLF cells (Fig. 1B) . When GFP-expressing MNNG/HOS-GFP cells were co-cultured with human normal NHLF cells, OBP-702 infection showed a cytopathic effect (confirmed by observation of round-shaped morphological changes) in MNNG/HOS-GFP cells, but not in NHLF cells (Fig. 1C) . These results indicate that OBP-702 was more cytopathic than OBP-301 for human osteosarcoma cells, but was not cytopathic for normal human cells.
Increased induction of apoptosis by OBP-702 when compared with OBP-301 or
Ad-p53
We next investigated whether OBP-702 induces more profound apoptosis when (Fig. 2B and 2C ). Cell cycle analysis also showed that OBP-702 (10 MOIs) induced the highest percentages of sub-G1 population in SaOS-2 cells when compared with Ad-p53 or OBP-301 at same doses (Fig. 2D) . These results suggest that OBP-702 induces increased apoptosis when compared with Ad-p53 or OBP-301 in human osteosarcoma cells.
p53 induction in human osteosarcoma cells infected with OBP-702
To investigate the molecular mechanism of OBP-702-induced apoptosis in human osteosarcoma cells, we evaluated p53 expression after OBP-702 infection in SaOS-2 (p53 null) and MNNG/HOS (p53 mutant) cells in which endogenous p53 expression level was confirmed by Western blot analysis ( Supplementary Fig. S3 ).
OBP-702 efficiently induced p53 expression in SaOS-2 and MNNG/HOS cells (Fig.   3A ). The level of p53 expression was higher in OBP-702-treated cells than in
Ad-p53-treated cells (Fig. 3A) . In spite of OBP-702-induced high p53 expression, (Fig. 3B) . The expression levels of miR-93 and miR-106b were increased in association with E2F1 activation in OBP-702-infected SaOS-2 and MNNG/HOS cells (Fig. 3C) . In contrast, E1A-deleted Ad-p53 infection did not increase expressions of E2F1 and E2F1-regulated miR-93 and miR-106b (data not shown). Next, we assessed whether upregulation of miR-93 and miR-106b efficiently suppresses p21 expression induced by Ad-p53-mediated p53 overexpression. Ad-p53
infection at MOIs of 10 and 100 efficiently induced p21 expression at 48 h after infection in SaOS-2 cells ( Supplementary Fig. S5 ). When SaOS-2 cells were infected with Ad-p53 at an MOI of 100 for 48 h, pre-transfection with miR-93, miR-106b or both efficiently suppressed Ad-p53-induced p21 expression (Fig. 3D) . Interestingly, both 
Increased induction of autophagy by OBP-702 when compared with OBP-301
Recently, we demonstrated that oncolytic adenovirus OBP-301 mainly induces programmed cell death in association with autophagy rather than apoptosis in human tumor cells (31) . Therefore, we next investigated whether OBP-702 induces more profound autophagy than does OBP-301. Western blot analysis revealed that OBP-702 infection showed increased autophagy, which was confirmed by conversion of LC3-I to
LC3-II (increased ratio of LC3-II/LC3-I) and p62 downregulation, when compared with
OBP-301 in MNNG/HOS cells (Fig. 4A ). Moreover, the expression level of the p53-induced modulator of autophagy, DRAM (32), was decreased after OBP-301
infection, but its expression was maintained after OBP-702 infection (Fig. 4A) . Since p53-mediated p21 overexpression is known to inhibit both apoptosis and autophagy (17, 18), we further evaluated whether miR-mediated p21 suppression is involved in the enhancement of p53-mediated autophagy induction. Ad-p53-induced autophagy was enhanced by miR-93 and miR-106b -mediated p21 suppression (Fig. 4B) . These results suggest that OBP-702 induces more profound autophagy than does OBP-301 and that this effect occurs via p53-mediated DRAM activation and miR-mediated p21 suppression. Ad-p53-treated tumors (Fig. 5C ). On histopathologic analysis, there were large necrotic areas in OBP-702-treated tumors, but not in OBP-301-or Ad-p53-treated tumors (Fig.   5D ). Moreover, the expression of the cell proliferation marker, Ki67, was also decreased, especially in OBP-702-treated tumor cells ( Supplementary Fig. S6 ). These results suggest that OBP-702 eliminates tumor tissues more efficiently when compared with OBP-301 or Ad-p53.
Discussion
We previously reported that telomerase-specific replication-competent oncolytic adenovirus OBP-301 has strong antitumor activity in a variety of human epithelial and non-epithelial malignant cells (12, 14, 27) . However, some human osteosarcoma cells were resistant to the cytopathic activity of OBP-301 (14) . In this study, we demonstrated that a novel p53-expressing oncolytic adenovirus, OBP-702, had increased in vitro and in vivo antitumor effects than did OBP-301 in human osteosarcoma cells ( Fig. 1 and 5 ). OBP-702 induced increased apoptosis in association with p53 upregulation and p21 downregulation when compared with replication-deficient Ad-p53 ( Fig. 2 and 3A) . E1A-dependent upregulation of miR-93
and miR-106b was involved in OBP-702-mediated suppression of p21 expression (Fig.   3 ). Moreover, p53-mediated DRAM activation with p21 suppression enhanced oncolytic adenovirus-mediated autophagy induction (Fig. 4) . Recent studies suggest that transgene-expressing armed oncolytic adenoviruses are a promising antitumor strategy for induction of oncolytic and transgene-induced cell death (33) . Although p53 overexpression has been shown to enhance antitumor activity of oncolytic adenoviruses (34), the molecular mechanisms by which p53 mediates enhancement of the antitumor effect remain unclear. Recently, we reported that OBP-702 induces profound apoptosis through p53-dependent BAX upregulation and E1A-dependent p21 and MDM2 downregulation in epithelial malignant cells (26) . Thus, oncolytic adenovirus-mediated p53 overexpression likely induces dual apoptotic and autophagic cell death pathways through p53-dependent BAX/DRAM activation and E1A-dependent p21/MDM2 suppression with E2F1-inducible miR-93/106b upregulation (Fig. 6 ).
OBP-702 efficiently suppressed the cell viability of both OBP-301-sensitive and OBP-301-resistant osteosarcoma cells (Fig. 1) . We previously reported that OBP-301-resistant SaOS-2 cells have no hTERT mRNA expression ( Table 1 Fig. 1 and Table 1 ). These results suggest that p53 overexpression overcomes resistance to OBP-301 in ALT-type SaOS-2 cells. Since the replication rate of OBP-702 was almost similar that of OBP-301 in ALT-type SaOS-2 cells ( Supplementary Fig. S4 ), p53-induced cell death pathway would suppress the cell viability of ALT-type human osteosarcoma cells.
OBP-702-mediated p53 overexpression induced two types of programmed cell deaths (i.e., apoptosis and autophagy), thereby contributing to the enhancement of the antitumor effect of OBP-301 in human osteosarcoma cells (Fig. 2 and 4) . Since p53-downstream target p21 functions as a suppressor of apoptosis and autophagy (17, 18) , p21 suppression may be a critical factor to induce dual programmed cell death pathways in response p53 overexpression. Suppression of p21 expression by genetic deletion or artificial p21-target microRNA has been shown to enhance the Ad-p53-induced apoptosis (18, 35) . Inactivation of p21 by adenoviral E1A has been shown to enhance apoptosis in chemotherapeutic drug-treated human colon cancer cells that overexpress p53 (36) . Genetic deletion of p21 has been also shown to induce autophagy in mouse embryonic fibroblasts treated with C(2)-ceramide or gamma-irradiation (17) . In contrast, p21 overexpression inhibited the Ad-p53-mediated apoptosis induction (18) . Thus, E1A-mediated p21 downregulation would enhance p53-induced apoptosis and autophagy in OBP-702-infected cells.
E1A-dependent E2F1 activation and subsequent upregulation of E2F1-inducible miRNAs efficiently suppressed p21 expression, leading to the enhancement of p53-induced apoptosis and autophagy, in OBP-702-infected osteosarcoma cells (Fig. 2, 3 and 4) . Recent studies suggest that the cross-talk between p53 and E2F1 play a role in the regulation of diverse cell fates (37) . For example, co-expression of p53 and E2F1 contributes to induction of apoptosis (38, 39) . We previously demonstrated that E2F1 enhanced Ad-p53-mediated apoptosis through p14ARF-dependent MDM2 downregulation (39) and that OBP-702 infection showed E1A-dependent MDM2 downregulation in association with apoptosis (26) . Recently, E2F1 has been shown to suppress MDM2 expression by suppressing the promoter activity (40) or by inducing upregulation of miR-25/32, which targets MDM2 (41).
Furthermore, E2F1-inducible miR-93/106b enhanced Ad-p53-induced apoptosis and autophagy via p21 suppression (Fig. 3D and 4B) . Therefore, the cooperation between the MDM2-p53-p21 pathway and the E2F1-miRNA pathway may be involved in the induction of apoptotic and autophagic cell death in response to OBP-702.
OBP-702-mediated p53 overexpression enhanced autophagy that was induced by oncolytic adenovirus in human osteosarcoma cells. OBP-702 infection induced increased expression of DRAM and decreased expression of p62 when compared with OBP-301 (Fig. 4) , suggesting that OBP-702-mediated p53 overexpression enhances autophagy through DRAM activation. We recently reported that OBP-301 induces autophagy through E1A-dependent activation of E2F1-miR-7 pathway and subsequent suppression of epidermal growth factor receptor (EGFR) (31) . Restoration of p53 expression enhances the sensitivity to EGFR inhibitors in human cancer cells (42) . Adenovirus-mediated p53 gene therapy exerts an antitumor effect in human osteosarcoma cells (46) . However, the antitumor activity of replication-deficient Ad-p53 is limited in some human osteosarcoma cells (47) . Ad-p53-mediated p53 overexpression increases the sensitivity of human osteosarcoma cells to the chemotherapeutic drugs, cisplatin and doxorubicin (48) . A synergistic antitumor effect between doxorubicin and roscovitine was also associated with autophagy induction in human osteosarcoma U2OS cells (49) . As OBP-702 induced more profound apoptosis and autophagy than did OBP-301 or Ad-p53 (Fig. 2 and 4 ), combination therapy with OBP-702 and chemotherapeutic agents may be more effective than monotherapy with OBP-702.
Moreover, a recent report has shown that p53-armed replication-competent oncolytic adenovirus is a safe antitumor agent in rodents and nonhuman primates (50) . However, for clinical application of OBP-702, it must be necessary to establish the systemic delivery method and confirm the host biological contributions in cancer patients.
Although there are some unsolved issues, the combination of p53-armed oncolytic adenovirus and chemotherapy may provide us a promising antitumor strategy against human osteosarcoma cells.
In conclusion, we clearly demonstrated that the p53-expressing oncolytic adenovirus OBP-702 has a much stronger antitumor effect than does OBP-301.
Oncolytic adenovirus-mediated p53 gene transduction may induce dual apoptotic and autophagic cell death pathways through p53-dependent activation of cell death inducers and E1A-dependent suppression of cell death inhibitors, resulting in the enhancement of antitumor effect. At 48 h after Ad-p53 infection, the expression levels of p53, p21, PARP and cleaved PARP (C-PARP) were examined by Western blot analysis. -actin was assayed as a loading control. By using ImageJ software, the expression level of C-PARP protein was calculated relative to its expression in the control miR-treated cells, whose expression level was designated as 1.0. before Ad-p53 infection. At 48 h after Ad-p53 infection at an MOI of 100, the expression levels of LC3, p62 and DRAM were examined by Western blot analysis.
β-actin was assayed as a loading control. By using ImageJ software, the ratio of LC3-II/LC3-I expressions was calculated relative to its expression in the mock-infected cells, whose expression level was designated as 1.0. 
